Convection-Enhanced Delivery for Targeted Delivery of Antiglioma Agents: The Translational Experience
Figure 3
(a) 4 patients of the 16 treated demonstrated an immediate decrease in contrast enhancing volume following CED of topotecan, classified as early responders. (b) Serial T1 weighted, contrast MRI sequences from a selected patient demonstrating significant response with complete resolution at 1.5 years. Recurrence was noted at 2.5 years posttreatment. (Figure reprinted with permission from Bruce et al. [6].)
